An interventional study of Enhanced Academic Detailing and Informational Intervention in Tobacco-Related Carcinoma and Smoking &Amp; Tobacco Cessation, sponsored by OHSU Knight Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by OHSU Knight Cancer Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.
Among the 899 studies in Smoking with a site in United States, this one is the 7th largest by enrollment of the 785 interventional ones that give a count, is one of 26 that started in 2023, is one of 494 with no phase, and was the 728th registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
Georgia State University · Sites in United States
Ages 21+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
899 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 112 · Phase 3 64 · Phase 4 67
First in 1993; this study’s year is marked. 26 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9,133 is above the median of 116 across 1,167 interventional studies indexed under Smoking.
Median enrollment 109 across the 785 interventional studies, 131 across the 108 observational. Of the 742 that completed or were terminated, 293 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 899 have an industry lead sponsor. The 10 most frequent:
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
OHSU Knight Cancer Institute has 1 study filed under Smoking — fewer than ten, so there is no comparison to draw.
57 of the studies in Smoking with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07119489Wake Forest University Health SciencesA Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial | 2026-11 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 57 to your calendar (.ics) → With an account.
Among the 899 studies in Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase IV clinical trial determines the impact of implementing a Quitline electronic (e)Referral system with an enhanced academic detailing implementation strategy on Quitline reach, tobacco cessation assistance and self-reported quit rates among patients in community health centers. It also examines the cost-effectiveness of Quitline eReferrals both with and without enhanced academic detailing. If this implementation strategy is effective, this strategy could be used to increase tobacco cessation treatment through the collaboration between state Quitlines and community health centers that serve large numbers of socioeconomically disadvantaged patients who use tobacco.
PRIMARY OBJECTIVES:
I. Implement a Quitline electronic (e)Referral system with enhanced academic detailing (AD) (intervention; n=10 community health centers [CHCs]) and without enhanced AD (comparison; n=10 CHCs) to compare rates of eReferral offers, eReferral acceptance, Quitline enrollment, orders for tobacco cessation medication, and receipt of in-clinic counseling among patients identified as currently using tobacco.
II. Assess the effectiveness of implementing a Quitline eReferral system with enhanced AD (intervention) versus without enhanced AD (comparison) on self-reported tobacco quit rates among all patients identified as current persons using tobacco using electronic health record (EHR) data.
III. Estimate the total annual costs and incremental cost-effectiveness of a Quitline eReferral system, with and without enhanced AD.
OUTLINE: Clinics are randomized to 1 of 2 arms.
ARM I: Clinics are notified via email that the eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding electronic health record (EHR) screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
ARM II: Clinics receive standard online materials and access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the Quitline eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Study Clinic Inclusion Criteria:
Study Patient Inclusion Criteria:
Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
Other: Informational Intervention
Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
Behavioral: Enhanced Academic Detailing · Other: Informational Intervention
* Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation * Follow-up booster sessions * Monthly performance audit and feedback
Also known as: EAD
Receive overview of Quitline services and use of Quitline eReferral via online materials
Number of Participants Who Accepted Electronic (e)Referral to Quitline
Number of patients who accepted a Quitline eReferral in intervention (EAD) versus comparator clinics among those using tobacco.
Time frame: At any point during the 26-month intervention period
Quitline eReferral Offered
Number of patients who were offered the Quitline eReferral.
Time frame: At any point during the 26-month intervention period
Quitline Enrollment
Number of patients who accepted the Quitline eReferral and enrolled in Quitline services.
Time frame: At any point during the 26-month intervention period
Receipt of In-office Counseling
Number of patients with an indication in the electronic health record (EHR) of receipt of counseling during an office visit.
Time frame: At any point during the 26-month intervention period
Tobacco Cessation Medication Ordered
Number of patients with a tobacco cessation medication in the 'medication orders' list of the EHR.
Time frame: At any point during the 26-month intervention period
Tobacco Cessation
Number of patients with EHR status change from current to former tobacco use.
Time frame: At any point during the 26-month intervention period or up to 6 months post-intervention
Annual Intervention Costs
Mean total annual costs in years 1-4 to implement the eReferral into the EHR and maintain eReferral system, with and without enhanced academic detailing.
Time frame: Years 1-4
Cost-effectiveness
Mean total annual costs over years 1-4 by study arm, overall and for patients enrolled in the Quitline.
Time frame: Years 1-4
Recruited clinics affiliated with OCHIN in Oregon. Clinics had ≥300 unique patients; ≥ 1 patient identified as smoking; \<50% private insurance. Eligible individuals are aged ≥ 18 years and noted as currently using tobacco at any time during the study.
| Milestone | Arm I (Quitline eReferral) | ARM II (Quitline eReferral Plus Enhanced AD) |
|---|---|---|
| Started | 4644 | 4489 |
| Completed | 4644 | 4489 |
| Not completed | 0 | 0 |
Number of patients who accepted a Quitline eReferral in intervention (EAD) versus comparator clinics among those using tobacco.
| Participants | Arm I (Quitline eReferral) | ARM II (Quitline eReferral Plus Enhanced AD) |
|---|---|---|
| Number of Participants Who Accepted Electronic (e)Referral to Quitline | 264 | 420 |
Number of patients who were offered the Quitline eReferral.
Results for this outcome have not been posted.
Number of patients who accepted the Quitline eReferral and enrolled in Quitline services.
Results for this outcome have not been posted.
Number of patients with an indication in the electronic health record (EHR) of receipt of counseling during an office visit.
Results for this outcome have not been posted.
Number of patients with a tobacco cessation medication in the 'medication orders' list of the EHR.
Results for this outcome have not been posted.
Number of patients with EHR status change from current to former tobacco use.
Results for this outcome have not been posted.
Mean total annual costs in years 1-4 to implement the eReferral into the EHR and maintain eReferral system, with and without enhanced academic detailing.
Results for this outcome have not been posted.
Mean total annual costs over years 1-4 by study arm, overall and for patients enrolled in the Quitline.
Results for this outcome have not been posted.
Collected over From enrollment until end of data collection (26 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I (Quitline eReferral) | 0/4,644 (0%) | 0/4,644 (0%) | 0/4,644 (0%) |
| ARM II (Quitline eReferral Plus Enhanced AD) | 0/4,489 (0%) | 0/4,489 (0%) | 0/4,489 (0%) |
| Age, Categorical(Participants) | Arm I (Quitline eReferral) | ARM II (Quitline eReferral Plus Enhanced AD) | Total |
|---|---|---|---|
| <=18 years | 36 | 31 | 67 |
| Between 18 and 65 years | 4046 | 3894 | 7940 |
| >=65 years | 562 | 564 | 1126 |
| Sex/Gender, Customized(Participants) | Arm I (Quitline eReferral) | ARM II (Quitline eReferral Plus Enhanced AD) | Total |
|---|---|---|---|
| Sex — Female | 2006 | 2088 | 4094 |
| Sex — Male | 2638 | 2401 | 5039 |
| Sex — Other | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm I (Quitline eReferral) | ARM II (Quitline eReferral Plus Enhanced AD) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 64 | 80 | 144 |
| Asian | 140 | 48 | 188 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 197 | 218 | 415 |
| White | 3650 | 3513 | 7163 |
| More than one race | 171 | 118 | 289 |
| Unknown or Not Reported | 422 | 512 | 934 |
| Ethnicity (NIH/OMB)(Participants) | Arm I (Quitline eReferral) | ARM II (Quitline eReferral Plus Enhanced AD) | Total |
|---|---|---|---|
| Hispanic or Latino | 430 | 428 | 858 |
| Not Hispanic or Latino | 3803 | 3523 | 7326 |
| Unknown or Not Reported | 411 | 538 | 949 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Limited data set was given by partner research organization under data use agreement that excludes disclosure of any data outside of this study.
Ran from Jun 2023 to primary completion in Aug 2025, 26 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 405 non-industry interventional studies with no phase under Smoking, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 26 months is close to that.
Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OHSU Knight Cancer Institute →